- Trial phase
- Approved / marketed
- Time to market
- Already on the market with significant commercial sales (court record cites annual sales exceeding $500M). The open timing question is generic entry: Lantheus's ANDA No. 217060 is pending FDA action, and Novartis's appeal of the patent-invalidity ruling is estimated to take 1-2 years.
- Why 3/10
- Lutathera is already FDA-approved and marketed with no PDUFA or pivotal readout scheduled for it in the next ~12 months, the next hard binary is the Federal Circuit appeal of the June 17, 2026 Delaware patent-invalidity ruling (court record estimates a 1-2 year timeline), and Lutathera is a small revenue line inside a ~$285B market-cap mega-cap (NVS Q2 2026 net sales $14.4B), so the rubric's approved-drug-with-no-pending-decision/low-concentration case scores 3.
For NVS holders this is a watch-item, not a thesis-driver: Lutathera is one of ~30 tracked drugs and immaterial to the stock, which is why the Q2 2026 filing flags it only as a risk item. The tradeable angle is elsewhere, Lantheus (LNTH) won the Delaware ruling and is itself being acquired by Curium ($102.50/share cash + up to $12 CVRs, close expected H1 2027), so the generic-commercialization story will land inside a private company. Watch the Federal Circuit appeal and FDA action on Lantheus ANDA 217060 for timing of any U.S. generic entry.
Price Chart
Executive Summary
Lutathera is Novartis's marketed radioligand cancer therapy (developed through its Advanced Accelerator Applications subsidiary) with annual sales the court record puts above $500M. Its defining recent event was negative: on June 17, 2026, a Delaware federal judge invalidated all asserted Lutathera patents on an "on-sale bar" (early commercial sales in European expanded-access programs), clearing a patent path for Lantheus's generic ANDA and leaving Curium's competing product non-infringing; Novartis has appealed (est. 1-2 years).
How It Works
Lutathera is a radioligand therapy, a form of targeted radiation. A tumor-seeking peptide that binds to somatostatin receptors (proteins found in high numbers on neuroendocrine tumor cells) is attached to the radioactive isotope lutetium-177, so the drug homes in on cancer cells and delivers radiation directly to them while largely sparing healthy tissue. It is given as an infusion.
Trial Status
Lutathera is a commercial drug; the active issue is now litigation, not trials. On June 17, 2026 the Delaware District Court issued a final judgment that all asserted claims of four patents covering Lutathera (U.S. 10,596,276; 12,151,003; 12,168,063; 12,161,732) are invalid under the on-sale bar, found Lantheus's generic product non-infringing on claim 12 of the '276 patent, and found Curium's product non-infringing on all claims. Novartis/ADACAP have filed an appeal (per its Q2 2026 6-K).
The Two-Sided Case
Upcoming Catalysts
- Federal Circuit decision on Novartis/ADACAP's appeal of the Delaware patent-invalidity ruling (filed; court record estimates 1-2 years, outside the 12-month window)
- FDA action on Lantheus's ANDA No. 217060 for a generic lutetium Lu 177 dotatate (date not disclosed)
- Potential Curium 505(b)(2) product entry, given Curium's product was found non-infringing
- Close of the Curium–Lantheus merger (expected H1 2027; $102.50/share cash + up to $12.00 CVRs), which determines who commercializes the generic
- Novartis quarterly earnings updates on the radioligand franchise
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report